{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:13:45Z","timestamp":1789982025455,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T00:00:00Z","timestamp":1545782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41416-018-0348-7","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T16:41:27Z","timestamp":1545324087000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype"],"prefix":"10.1038","volume":"120","author":[{"given":"David","family":"P\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Tobe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Fern\u00e1ndez-Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sebio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Cirera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00ed","family":"Barnadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,26]]},"reference":[{"key":"348_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J. Cancer 136, E359\u2013E386 (2015).","journal-title":"Int J. Cancer"},{"key":"348_CR2","unstructured":"Scnall, S. & MacDonald, J. S. Gastrointestinal cancers: Colorectal carcinoma, In Manual of Oncologic Therapeutics 3rd edn. (eds McDonald, J. S., Haller, D. G. & Mayer, R. J.) (Lippincott Company, Michigan, 2004)."},{"key":"348_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand, C. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22, 229\u2013237 (2004).","journal-title":"J. Clin. Oncol."},{"key":"348_CR4","first-page":"5944","volume":"47","author":"T Kunimoto","year":"1987","unstructured":"Kunimoto, T. et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47, 5944\u20135947 (1987).","journal-title":"Cancer Res."},{"key":"348_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1172\/JCI915","volume":"101","author":"L Iyer","year":"1998","unstructured":"Iyer, L. et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101, 847\u2013854 (1998).","journal-title":"J. Clin. Invest."},{"key":"348_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","volume":"91","author":"E Marcuello","year":"2004","unstructured":"Marcuello, E. et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678\u2013682 (2004).","journal-title":"Br. J. Cancer"},{"key":"348_CR7","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando, Y. et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921\u20136926 (2000).","journal-title":"Cancer Res."},{"key":"348_CR8","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti, F. et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382\u20131388 (2004).","journal-title":"J. Clin. Oncol."},{"key":"348_CR9","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","volume":"10","author":"E Rouits","year":"2004","unstructured":"Rouits, E. et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151\u20135159 (2004).","journal-title":"Clin. Cancer Res."},{"key":"348_CR10","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","volume":"24","author":"G Toffoli","year":"2006","unstructured":"Toffoli, G. et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24, 3061\u20133068 (2006).","journal-title":"J. Clin. Oncol."},{"key":"348_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/djm115","volume":"99","author":"JM Hoskins","year":"2007","unstructured":"Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G. & McLeod, H. L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 99, 1290\u20131295 (2007).","journal-title":"J. Natl. Cancer Inst."},{"key":"348_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FTD.0b013e318068623b","volume":"29","author":"TW Kim","year":"2007","unstructured":"Kim, T. W. & Innocenti, F. Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit. 29, 265\u2013270 (2007).","journal-title":"Ther. Drug Monit."},{"key":"348_CR13","unstructured":"United States Food and Drug Administration: Camptosar label. \n                    http:\/\/www.fda.gov\/cder\/foi\/label\/2005\/020571s024,027,028lbl.pdf"},{"key":"348_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/bjc.2011.206","volume":"105","author":"E Marcuello","year":"2011","unstructured":"Marcuello, E. et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil\/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105, 53\u201357 (2011).","journal-title":"Br. J. Cancer"},{"key":"348_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/JCO.2009.23.6125","volume":"28","author":"G Toffoli","year":"2010","unstructured":"Toffoli, G. et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil\/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 866\u2013871 (2010).","journal-title":"J. Clin. Oncol."},{"key":"348_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1998","unstructured":"Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1998).","journal-title":"Nucleic Acids Res."},{"key":"348_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan, G., Ryan, M., Seddon, R., Hume, R. & Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert\u2019s syndrome. Lancet 347, 578\u2013581 (1996).","journal-title":"Lancet"},{"key":"348_CR18","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med."},{"key":"348_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000368674","volume":"88","author":"KP Kim","year":"2015","unstructured":"Kim, K. P. et al. A phase I study of UGT1A1 *28\/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI. Oncology 88, 164\u2013172 (2015).","journal-title":"Oncology"},{"key":"348_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trsl.2013.12.009","volume":"164","author":"CY Lu","year":"2014","unstructured":"Lu, C. Y. et al. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil\/leucovorin with irinotecan in a first-line setting. Transl. Res. 164, 169\u2013176 (2014).","journal-title":"Transl. Res."},{"key":"348_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.tranon.2015.11.002","volume":"8","author":"CY Lu","year":"2015","unstructured":"Lu, C. Y. et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting. Transl. Oncol. 8, 474\u2013479 (2015).","journal-title":"Transl. Oncol."},{"key":"348_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/1078-0432.CCR-16-1012","volume":"23","author":"G Toffoli","year":"2017","unstructured":"Toffoli, G. et al. Genotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Clin. Cancer Res. 23, 918\u2013924 (2017).","journal-title":"Clin. Cancer Res."},{"key":"348_CR23","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1245\/s10434-015-5072-4","volume":"23","author":"JM Phelip","year":"2016","unstructured":"Phelip, J. M. et al. High resectability rate of initially unresectable colorectal liver metastases after UGT1A1-adapted high-dose irinotecan combined with LV5FU2 and cetuximab: a multicenter phase II study (ERBIFORT). Ann. Surg. Oncol. 23, 2161\u20132166 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"348_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1634\/theoncologist.2011-0141","volume":"16","author":"E Assenat","year":"2011","unstructured":"Assenat, E. et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 16, 1557\u20131564 (2011).","journal-title":"Oncologist"},{"key":"348_CR25","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","volume":"28","author":"LM Henricks","year":"2017","unstructured":"Henricks, L. M., Opdam, F. L., Beijnen, J. H., Cats, A. & Schellens, J. H. M. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann. Oncol. 28, 2915\u20132922 (2017).","journal-title":"Ann. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0348-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:54Z","timestamp":1684616634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0348-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,26]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0348-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,26]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All subjects gave written consent. The study protocol was approved by the hospital\u2019s ethics committee. The study was performed according to the guidelines of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"All subjects gave written consent for publication:","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.P. has declared scientific advisory role for Amgen, Sanofi, Merck Serono, and Servier. M.T. has declared scientific advisory role for Amgen, Sanofi, and F. Hoffmann-La Roche Ltd. A.B. has declared scientific advisory role and has participated on the speaker\u2019s bureau for Novartis, Pfizer, F. Hoffmann-La Roche Ltd, MSD, Pierre Fabre, Lilly. and Pallex. A.B. has received institutional grant support from F. Hoffmann-La Roche Ltd, Pfizer, Lilly. and Bristol Myers Squibb. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}